ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag politics microbiology neuroscience disease medicine

Haydeh Payami is wearing a purple dress and an orange and pink scarf and standing in front of a whiteboard.
A Microbial Link to Parkinson’s Disease
Mariella Bodemeier Loayza Careaga, PhD | Dec 4, 2023 | 6 min read
Haydeh Payami helped uncover the genetic basis of Parkinson’s disease. Now, she hopes to find new ways to treat the disease by studying the gut microbiome.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Updated Mar 8
A healthcare worker holds up three syringes with clear medicine
To Booster or Not: Scientists and Regulators Debate
Jef Akst | Sep 16, 2021 | 7 min read
President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.
Those We Lost in 2019
Ashley Yeager | Dec 30, 2019 | 6 min read
The scientific community said goodbye to Sydney Brenner, Paul Greengard, Patricia Bath, and a number of other leading researchers this year.
Bioterrorism Research: New Money, New Anxieties
John Dudley Miller | Apr 6, 2003 | 8 min read
Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
Antibody Alternatives
Paul Ko Ferrigno and Jane McLeod | Feb 1, 2016 | 10+ min read
Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.
Elias A. Zerhouni
Ted Agres | Jul 7, 2002 | 4 min read
In the mid-1980s, cardiologists faced a particularly vexing problem: how to measure, accurately and noninvasively, the thickness of heart tissue as it changed over time. Elias A. Zerhouni, a young radiology professor at Johns Hopkins School of Medicine, struggled over the issue with a small team of physicists. "One day, he walked into the room with this incredible smile on his face, like you would have if you made a great molecular discovery," recalls Myron Weisfeldt, director of Hopkins' Depart
NAS Honors 15 For Contributions To Science
Eugene Russo | Apr 26, 1998 | 7 min read
Seven life scientists are among the 15 honorees for this year's National Academy of Sciences award ceremony set for today at the NAS's 135th annual meeting in Washington, D.C. The meeting also includes the induction of academy members elected last year (E.R. Silverman, The Scientist, 11[9]:1, April 28, 1997). The academy is presenting its highest honor, the Public Welfare Medal, to David A. Hamburg, president emeritus of the Carnegie Corp. of New York. Hamburg, 72, is being recognized "for his
AIDS Investigators Cautiously Applauding Recent Advances
Steven Benowitz | Sep 29, 1996 | 10+ min read
Discoveries announced at conference leave scientists feeling optimistic; yet their enthusiasm is tempered by several persistent concerns. AIDS researchers have many reasons to be encouraged. Studies show that treatments combining new and old drugs can control HIV levels in the blood. Moreover, many scientists and activists note, prevention efforts have helped reduce HIV infection rates. Yet the enthusiasm is tempered by several caveats. Drugs are expensive and have harsh side effects, leading

Run a Search

ADVERTISEMENT